Udenafil ( DrugBank: Udenafil )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
86	Pulmonary arterial hypertension	2
210	Single Ventricle	4

86. Pulmonary arterial hypertension

---

Clinical trials : 1,205 /  Drugs : 684 - (DrugBank : 124) / Drug target genes : 100 - Drug target pathways : 193

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02304198 (ClinicalTrials.gov)	April 2014	26/11/2014	Clinical Trial to Evaluate the Long-term Safety of Udenafil in Patient With PAH	A Single-arm, Open-label, Extension Study to Evaluate the Long-term Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)	Pulmonary Arterial Hypertension	Drug: Udenafil	Dong-A ST Co., Ltd.	NULL	Completed	18 Years	N/A	Both	59	Phase 2/Phase 3	Korea, Republic of
2	NCT01553721 (ClinicalTrials.gov)	August 2011	1/1/2012	Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)	A Placebo-controlled, Double-blind, Phase II Clinical Study to Evaluate the Efficacy and Safety of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)	Pulmonary Arterial Hypertension	Drug: udenafil;Drug: placebo	Dong-A ST Co., Ltd.	NULL	Completed	18 Years	N/A	Both	63	Phase 2	Korea, Republic of

210. Single Ventricle

---

Clinical trials : 51 /  Drugs : 53 - (DrugBank : 22) / Drug target genes : 32 - Drug target pathways : 67

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03430583 (ClinicalTrials.gov)	February 20, 2018	22/1/2018	Evaluation of Fontan-Associated Liver Disease	Imaging and Biomarker Evaluation of Hepatic Stiffness in Children Enrolled in the Fontan Udenafil Exercise Longitudinal Study	Single Ventricle Heart Disease	Drug: MZ101	Mezzion Pharma Co. Ltd	National Heart, Lung, and Blood Institute (NHLBI)	Active, not recruiting	12 Years	N/A	All	100		United States;Canada
2	NCT03013751 (ClinicalTrials.gov)	January 2017	5/1/2017	A Extension Study of Udenafil in Adolescents	A Phase III Extension Study of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation	Functional Single Ventricle Heart Disease	Drug: Udenafil	Mezzion Pharma Co. Ltd	National Heart, Lung, and Blood Institute (NHLBI)	Active, not recruiting	12 Years	18 Years	All	300	Phase 3	United States;Canada;Korea, Republic of
3	NCT02741115 (ClinicalTrials.gov)	July 22, 2016	10/4/2016	Fontan Udenafil Exercise Longitudinal Assessment Trial	Fontan Udenafil Exercise Longitudinal Assessment Trial (FUEL)	Single Ventricle Heart Disease	Drug: Udenafil;Drug: Placebo	Mezzion Pharma Co. Ltd	National Heart, Lung, and Blood Institute (NHLBI)	Completed	12 Years	18 Years	All	400	Phase 3	United States;Canada;Korea, Republic of
4	NCT02201342 (ClinicalTrials.gov)	July 2014	24/7/2014	Pharmacokinetic/Pharmacodynamic Study of Udenafil in Adolescents	A Phase I/II Dose Escalation Trial of Udenafil in Adolescents With Single Ventricle Physiology After Fontan Palliation	Single Ventricle Heart Disease After Fontan Surgery	Drug: Udenafil	Mezzion Pharma Co. Ltd	National Heart, Lung, and Blood Institute (NHLBI);Pediatric Heart Network;National Heart, Lung, and Blood Institute (NHLBI);Pediatric Heart Network	Completed	14 Years	18 Years	Both	36	Phase 1/Phase 2	United States;Canada

Back to top